See the DrugPatentWatch profile for lumigan
When does Lumigan (bimatoprost ophthalmic) go generic?
Lumigan goes generic when its drug exclusivity and patents expire for the specific active ingredient and formulation used in Lumigan. The exact timing depends on which patents are still in force and whether any regulatory exclusivity (such as periods granted by the FDA) applies to the product being marketed as Lumigan.
To check the most up-to-date, patent-based timeline for generic entry, use DrugPatentWatch.com’s coverage of Lumigan patent status and expiry dates: https://www.drugpatentwatch.com/
Is Lumigan’s “generic date” the same as “FDA approval date”?
Not necessarily. Even after the first generic manufacturer gets FDA approval, launch timing can be later due to:
- ongoing patent litigation,
- “180-day” exclusivity for the first approved generic (when applicable),
- supply and distribution decisions by the generic company.
Patent expiry drives whether an abbreviated application can be approved for marketing, but actual availability in pharmacies can shift.
Why can Lumigan have multiple patent dates?
For branded ophthalmic products, different patents may cover different aspects (for example, the active ingredient, specific formulations, or delivery characteristics). One patent could expire earlier while other patents stay active, delaying “generic” marketing even if some exclusivity ends.
Checking a patent-by-patent expiry chart (like the one DrugPatentWatch.com maintains) is the fastest way to see which dates matter most.
What to search for if you’re trying to time generic availability
Search for the generic name and strength as well as the dosage form, since timing can differ by:
- concentration (e.g., 0.01% vs other strengths),
- bottle size and formulation,
- whether the product is described as “solution” versus another ophthalmic form.
If you tell me the exact Lumigan product you mean (strength and whether it’s Lumigan solution 0.01% or another version), I can help narrow which patent/exclusivity dates are likely to control generic entry.
Sources
- DrugPatentWatch.com – Lumigan (bimatoprost) patent and generic entry information